Lifesci Capital Issues Negative Outlook for DNTH Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Investment analysts at Lifesci Capital dropped their Q3 2025 earnings per share (EPS) estimates for Dianthus Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($0.88) for the quarter, down from their prior estimate of ($0.87). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. Lifesci Capital also issued estimates for Dianthus Therapeutics’ Q4 2025 earnings at ($0.90) EPS and FY2025 earnings at ($3.49) EPS.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million.

A number of other research analysts have also recently commented on DNTH. William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an “outperform” rating on the stock. Robert W. Baird reduced their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $53.00.

Dianthus Therapeutics Trading Up 2.4%

Shares of Dianthus Therapeutics stock opened at $20.74 on Friday. The business’s fifty day moving average price is $19.49 and its 200 day moving average price is $20.00. The stock has a market capitalization of $667.62 million, a P/E ratio of -6.38 and a beta of 1.43. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $32.27.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. MetLife Investment Management LLC lifted its stake in shares of Dianthus Therapeutics by 3.1% in the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock worth $313,000 after acquiring an additional 433 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in shares of Dianthus Therapeutics by 3.4% in the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company’s stock worth $332,000 after acquiring an additional 602 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after acquiring an additional 618 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Dianthus Therapeutics by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company’s stock worth $1,336,000 after acquiring an additional 748 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Dianthus Therapeutics by 7.4% in the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock worth $251,000 after acquiring an additional 790 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.